U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06868381) titled 'A Trial of Baricitinib in Patients with Cardiac Sarcoidosis' on March 03.
Brief Summary: The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:
- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT?
Participants will:
* Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks
* Visit the clinic every two to four weeks for checkups and tests...